This section is intended for Great Britain healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

Select an indication to find out more...

ADCETRIS FOR ADULTS WITH

Relapsed/refractory Hodgkin Lymphoma (R/R HL)

ADCETRIS FOR ADULTS WITH

Specific types of T-cell Lymphomas

ADCETRIS has received a conditional marketing authorisation

Indications

ADCETRIS is indicated for the treatment of adult patients with:1

  • Previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD)
  • Relapsed or refractory CD30+ HL:
    • Following autologous stem cell transplant (ASCT) or
    • Following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option
  • CD30+ HL at increased risk of relapse or progression following ASCT
  • Previously untreated systemic anaplastic large cell lymphoma (sALCL) in combination with cyclophosphamide, doxorubicin and prednisone (CHP)
  • Relapsed or refractory sALCL
  • CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy

C-APROM/UK/ADCE/0090 - December 2021

 

Find out the reimbursement and funding status for ADCETRIS in Great Britain

Use our handy tool to discover the reimbursement status for all indications of ADCETRIS throughout Great Britain

Find reimbursement info

Adverse events should be reported. In Great Britain, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Takeda by e-mail AE.GBR-IRL@takeda.com.